Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

Objectives Graves’ disease induced by Alemtuzumab (GD-IA) is one of the most frequently observed adverse events in patients with multiple sclerosis (MS) treated with this drug. The aim of this study is the sequencing and description of these events, along with the identification of the risk factors...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of endocrinological investigation Vol. 45; no. 10; pp. 1977 - 1990
Main Authors:	Rodríguez de Vera Gómez, P., García-González, J. J., Ravé-García, R., López Ruiz, R., Torres-Cuadro, A., Eichau-Madueño, S., García-García, C., Martín-Hernández, T.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-10-2022 Springer Nature B.V
Subjects:	Diagnosis Endocrinology Graves disease Internal Medicine Medicine Medicine & Public Health Metabolic Diseases Monoclonal antibodies Multiple sclerosis Observational studies Original Article Patients Risk factors Thyroid diseases Thyroid gland Thyroid-stimulating hormone Thyroidectomy Multiple sclerosis Alemtuzumab Autoimmune hyperthyroidism TSH monitoring
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!